Literature DB >> 10581223

Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules.

I Durán1, E M Martínez-Cáceres, J Río, N Barberà, M E Marzo, X Montalban.   

Abstract

Adhesion molecules are important in the trafficking of peripheral leucocytes into the central nervous system, a major event in the pathogenesis of multiple sclerosis, which is an inflammatory and demyelinating disease. The latest MRI evidence supports clinical divergence between forms of multiple sclerosis with relapses and the primary progressive form without relapses, which shows fewer and smaller inflammatory lesions. With the aim of elucidating whether different pathogenic mechanisms are involved in primary progressive multiple sclerosis, we compared membrane expression of the adhesion molecules ICAM-1 (CD54), LFA-1alpha (CD11a), VLA-4 [alpha(4)/beta(1) integrin (CD49d/CD29)], L-selectin (CD62L) and ICAM-3 (CD50) in peripheral blood and the serum-soluble forms ICAM-1, L-selectin, VCAM-1 and ICAM-3 in 89 patients (39 with the primary progressive form, 25 with the secondary progressive form and 25 with the relapsing-remitting form) and 38 healthy controls. We found a significant decrease in leucocyte surface expression of most of the adhesion molecules tested and an increase in soluble ICAM-1 and L-selectin levels in secondary progressive and relapsing-remitting multiple sclerosis compared with primary progressive multiple sclerosis, which gave results similar to those in controls. These results, which are supported by MRI evidence, show that trafficking of autoreactive leucocytes through the blood-brain barrier is crucial to the pathogenesis of secondary progressive and relapsing-remitting forms of multiple sclerosis, whereas other mechanisms leading to progressive axonal damage would account for primary progressive forms of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10581223     DOI: 10.1093/brain/122.12.2297

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  8 in total

Review 1.  Differentiation of multiple sclerosis subtypes: implications for treatment.

Authors:  Andreas Bitsch; Wolfgang Brück
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis.

Authors:  D R Booth; A T Arthur; S M Teutsch; C Bye; J Rubio; P J Armati; J D Pollard; R N S Heard; G J Stewart
Journal:  J Mol Med (Berl)       Date:  2005-08-02       Impact factor: 4.599

3.  Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study.

Authors:  Y Zoukos; T N Thomaides; D Kidd; M L Cuzner; A Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

4.  Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis.

Authors:  Erin E McCandless; Laura Piccio; B Mark Woerner; Robert E Schmidt; Joshua B Rubin; Anne H Cross; Robyn S Klein
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

5.  Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis.

Authors:  Manuel Comabella; E Julià; M Tintoré; L Brieva; N Téllez; J Río; C López; A Rovira; X Montalban
Journal:  J Neurol       Date:  2008-05-20       Impact factor: 4.849

6.  TNF-alpha converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis.

Authors:  Manuel Comabella; Cristina Romera; Montse Camiña; Hector Perkal; María A Moro; Juan C Leza; Ignacio Lizasoain; Mireia Castillo; Xavier Montalban
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

7.  The IL-27/IL-27R axis is altered in CD4+ and CD8+ T lymphocytes from multiple sclerosis patients.

Authors:  Marie-Laure Clénet; Cyril Laurent; Florent Lemaitre; Negar Farzam-Kia; Olivier Tastet; Odile Devergne; Boaz Lahav; Marc Girard; Pierre Duquette; Alexandre Prat; Catherine Larochelle; Nathalie Arbour
Journal:  Clin Transl Immunology       Date:  2021-03-05

8.  Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.

Authors:  Jeppe Romme Christensen; Lars Börnsen; Rikke Ratzer; Fredrik Piehl; Mohsen Khademi; Tomas Olsson; Per Soelberg Sørensen; Finn Sellebjerg
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.